Le Lézard

Vertex to Participate in TD Cowen 46th Annual Health Care Conference on March 3

Vertex Pharmaceuticals Incorporated today announced management participation in TD Cowen's 46th Annual Health Care Conference ...

Vertex Autoimmune Deal With WuXi Adds New Angle To VRTX Valuation Story

Vertex Pharmaceuticals (NasdaqGS:VRTX) has signed a license and research agreement with WuXi Biologics for a trispecific T cell engager targeting B cell mediated autoimmune diseases. The deal gives ...

Vertex Pharmaceuticals Signals Confident Growth Beyond CF

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

CRSP Posts Wider-Than-Expected Loss in Q4, Sales Miss Estimates

CRISPR Therapeutics posts a wider Q4 loss and revenues miss, but Casgevy sales climb, with label expansion plans and pipeline updates ahead.

Vertex Pharma (VRTX) Renal Pipeline Seen as Major Growth Driver by Barclays

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) ranks among the best high growth high margin stocks to buy now.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q4 2025 earnings call transcript

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q4 2025 Earnings Call Transcript February 12, 2026 Vertex Pharmaceuticals ...

Vertex Pharmaceuticals Q4 Earnings Call Highlights

Vertex Pharmaceuticals (NASDAQ:VRTX) management emphasized revenue growth, expanding product diversification, and multiple ...

Vertex outlines 8% to 9% revenue growth for 2026 as non-CF products gain momentum

Q4 2025 earnings call highlights: 2026 revenue outlook, ALYFTREK progress, CASGEVY/JOURNAVX growth, and renal pipeline—read ...

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

ZUG, Switzerland and BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the fourth quarter and full year ended December 31, 2025.